CA
Therapeutic Areas
BioVie Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bezisterim (NE3107) | Alzheimer's Disease | Phase 3 |
| BIV201 | Refractory Ascites due to Liver Cirrhosis | Phase 2b |
Leadership Team at BioVie
CD
Cuong Do
President & Chief Executive Officer
JM
Joseph M. Palumbo
Executive Vice President, Research & Development and Chief Medical Officer
WK
Wendy Kim
Chief Financial Officer
PM
Penelope Markham
Senior Vice President Liver Disease and Long COVID Programs
DM
David Morse
Chief Regulatory Officer and Senior Vice President
CR
Chris Reading
Senior Vice President Alzheimer's Disease Program